logo-loader
viewAngel Mining

Angel Mining raises £2.1 mln to boost Greenland mine development projects

sterling350_4df1ce2adc5dd.jpg

 

Angel Mining (LON:ANGM) has raised £2.1 million through an institutional share placing. 

In total, Angel is issuing 109 million new shares at 2 pence each. The funds have been earmarked for further development work at its two mine development projects in Greenland.

At the Black Angel zinc and lead mine the money will help it build infrastructure, a cable car is currently being installed to connect the mine entrance to the mine camp. At the Nalunaq gold mine, which poured first gold two weeks ago, the cash money will help Angel expand production towards its targeted 24,000 ounce annual run-rate by the second half of 2011.

"Cash generation from gold sales will grow quickly but this additional capital is required to build up production at Nalunaq and to finance the continued development of the high grade Black Angel lead-zinc mine, which is expected to commence production in early 2013." 

“We anticipate that we will shortly be generating cash from Nalunaq and that will be an important source of finance for the development of Black Angel."

Last month Angel Mining revealed that gold production had begun at Nalunaq, although there were still some parts of the plant where further improvements could be made.

"The plant is designed to process 200 tonnes of ore per day and, subject to grade, it is expected to build up production to approximately 2,000 ounces of gold per month," said the company. 

 

Quick facts: Angel Mining

Price: - -

AIM:ANGM
Market: AIM
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharma CEO confident as he looks ahead to new Traumakine study

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen caught up with Proactive London's Andrew Scott soon after announcing they've amended the protocol for a second phase III study of its drug for acute respiratory distress syndrome (ARDS). The tweak's in response to...

18 hours, 4 minutes ago

2 min read